prostaglandin-h2 and 20-hydroxy-5-8-11-14-eicosatetraenoic-acid

1. The cytochrome P-450 metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), was found to be a potent, dose-dependent inhibitor of platelet aggregation and inhibitor of thromboxane biosynthesis induced by arachidonic acid (IC50 5.2 +/- 1.5 microM), A23187 (IC50 16.2 +/- 5.4 microM), and U46619 (IC50 7.8 +/- 2.4 microM). 20-HETE did not inhibit thrombin-induced aggregation. 2. The human platelet metabolized 20-HETE to a series of novel metabolites formed by cyclo-oxygenase as well as lipoxygenase pathways. The structures of the metabolites were identified by mass spectrometry as 20-hydroxy-thromboxane B2, 12,17-dihydroxyheptadecatrienoic acid, 12,20-dihydroxyeicosatetraenoic acid, and 11,20-dihydroxyeicosatetraenoic acid. 3. The identification of the 11-hydroxy metabolite of 20-HETE suggests that 20-HETE is less efficiently cyclized to an endoperoxide intermediate by cyclo-oxygenase than is arachidonate. 4. Although some biological activity of 20-HETE may be related to competition with endogenous arachidonate for cyclo-oxygenase metabolism, the predominant mechanism of action of 20-HETE appears to be through antagonism of the prostaglandin H2/thromboxane A2 receptor.

Topics: Adult; Arachidonate 12-Lipoxygenase; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Cyclic AMP; Fatty Acids, Unsaturated; Humans; Hydrazines; Hydroxyeicosatetraenoic Acids; In Vitro Techniques; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin H2; Prostaglandin-Endoperoxide Synthases; Prostaglandins H; Thromboxane A2